Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ≥65 years from GRIFFIN and PERSEUS
Paula Rodríguez‐Otero, Peter M. Voorhees, Mario Boccadoro, Jacob P. Laubach, Hermann Einsele, Douglas W. Sborov, Meletios A Dimopoulos, Annemiek Broijl, Roberto Mina, Andrew Spencer, Fredrik Schjesvold, Rebecca Silbermann, Francesca Gay, Luciano J. Costa, Aurore Perrot, Yanfang Liu, Jianping Wang, Anna Sitthi-Amorn, Robin Carson, Annelore Cortoos, Saad Z. Usmani, Paul G. Richardson, Philippe Moreau, Pieter Sonneveld, Jonathan L. Kaufman (2025). Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ≥65 years from GRIFFIN and PERSEUS. , 25(10), DOI: https://doi.org/10.1016/j.clml.2025.04.007.
Article25 days agoIsatuximab (Isa) subcutaneous (SC) via an on-body delivery system (OBDS) vs Isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): Results of the randomized, non-inferiority, phase 3 IRAKLIA study.
Sikander Ailawadhi, Ivan Špıčka, Jin Lu, Albert Oriol, Silvia Ling, Fredrik Schjesvold, Alejandro Berkovits, Marek Hus, Meletios A Dimopoulos, Péter Rajnics, Vânia Hungria, Maria Del Rosario Custidiano, Gurdeep Parmar, Xavier P. Leleu, Tondre T. Buck, Jiří Minařík, Rick Zhang, Dorothée Sémiond, Maya Stefanova-Urena, Philippe Moreau (2025). Isatuximab (Isa) subcutaneous (SC) via an on-body delivery system (OBDS) vs Isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): Results of the randomized, non-inferiority, phase 3 IRAKLIA study.. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.7506.
Article25 days agoIsatuximab subcutaneous by on-body injector in Relapsed/Refractory multiple myeloma in the Phase 3 iraklia study: Effect of body weight on pharmacokinetics and clinical outcome
Jin Lu, Albert Oriol, Alejandro Berkovits, Andrew Spencer, César Cinesi Gómez, Chunrui Li, Claudio Cerchione, Fei Li, Fredrik Schjesvold, Gurdeep Parmar, Ivan Špıčka, Marek Hus, Maria Del Rosario Custidiano, Meletios A Dimopoulos, Péter Rajnics, Sevgi Kalayoğlu Beşışık, Sikander Ailawadhi, Silvia Ling, Vânia Hungria, Xavier Leleu, Florence Suzan Teisserenc, Maya Stefanova-Urena, Rick Zhang, Victorine Koch, Dorothée Sémiond (2025). Isatuximab subcutaneous by on-body injector in Relapsed/Refractory multiple myeloma in the Phase 3 iraklia study: Effect of body weight on pharmacokinetics and clinical outcome. , 146(Supplement 1), DOI: https://doi.org/10.1182/blood-2025-5812.
Article25 days agoDaratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Aquila outcomes based on mayo 2018/IMWG 2020 risk stratification, IMWG 2020 plus cytogenetic criteria, and age
Peter M. Voorhees, Meletios A Dimopoulos, Yaël C. Cohen, Fredrik Schjesvold, Vânia Hungria, Irwindeep Sandhu, Jindriska Lindsay, Ross Baker, Kenshi Suzuki, Hiroshi Kosugi, Mark‐David Levin, Meral Beksaç, Keith Stockerl‐Goldstein, Hila Magen, Albert Oriol, Gábor Mikala, Gonzalo Garate, Koen Theunissen, Ivan Špıčka, Anne K. Mylin, Simon Hallam, Sara Galimberti, Katarina Uttervall, Bartosz Puła, Abdullah Khan, Eva Medvedova, J Christine Ye, Andrew J. Cowan, Philippe Moreau, María‐Victoria Mateos, Hartmut Goldschmidt, Diego Vieyra, Abid Raval, Linlin Sha, Liang Li, Els Rousseau, Robyn M. Dennis, Robin Carson, S. Vincent Rajkumar (2025). Daratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Aquila outcomes based on mayo 2018/IMWG 2020 risk stratification, IMWG 2020 plus cytogenetic criteria, and age. , 146(Supplement 1), DOI: https://doi.org/10.1182/blood-2025-372.
Article25 days agoErratum: Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study
Sikander Ailawadhi, Ivan Špıčka, Andrew Spencer, Jin Lu, Albert Oriol, Silvia Ling, Fredrik Schjesvold, Alejandro Berkovits, Marek Hus, Chunrui Li, Meletios A Dimopoulos, Péter Rajnics, Sevgi Kalayoğlu Beşışık, Vânia Hungria, Maria Del Rosario Custidiano, Gurdeep Parmar, Xavier Leleu, Fei Li, Claudio Cerchione, César Cinesi Gómez, Tadao Ishida, María‐Victoria Mateos, Tondre T. Buck, Richard LeBlanc, Jiří Minařík, Hartmut Goldschmidt, Rick Zhang, Dorothée Sémiond, Florence Suzan, Maya Stefanova-Urena, Vera Hermina Kalika Koch, Philippe Moreau (2025). Erratum: Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study. , 43 (27), DOI: https://doi.org/10.1200/jco-25-01767.
Corrigendum25 days ago